LLY
Lilly keeps adding chips to the table
Eli Lilly is doing what big pharma does when it wants to stay scary: it keeps buying time, talent, and optionality. This time, the company announced separate licensing and research agreements with South Korea’s Hanmi Pharm and China’s Haisco Pharmaceutical Group, giving Lilly a bigger pipeline to noodle around with while everyone else is still trying to figure out what the next blockbuster drug even looks like.
Two deals, one very clear message
With Hanmi, Lilly is getting exclusive worldwide rights outside Korea to sonefpeglutide, a biologic candidate being studied for short bowel syndrome. Hanmi gets $75 million upfront and could eventually land up to $1.185 billion in milestones plus royalties. That’s not pocket change; that’s the kind of number that says, “We think this thing could matter a lot.”
The Haisco tie-up is even broader. Lilly and Haisco are launching a multi-program research alliance that could cover up to five target programs, with Lilly taking the lead on development and commercialization. Haisco could receive up to $87 million upfront and near-term payments, plus as much as $2.967 billion in milestones. In other words: Lilly is paying for a deeper bench.
Retevmo adds some oncology shine
As if the pipeline news weren’t enough, Lilly also highlighted Phase 3 data for Retevmo. The LIBRETTO-432 trial showed the drug cut the risk of disease recurrence or death by 83% in early-stage RET fusion-positive lung cancer. That’s the kind of data that makes investors sit up a little straighter, even if the stock was still down 2.73% in premarket trading.
Why you should care
For investors, this is the classic pharma playbook: widen the pipeline, keep the patent cliff gremlins at bay, and hope one of these collaborations turns into a future money printer. Big picture: Lilly isn’t just selling drugs — it’s building a pipeline machine, and today’s news says that machine is still very much in overdrive.